Teva Presents New SOLARIS Data Showing TEV-'749 Maintained Schizophrenia Stabilization And Supported Remission In Long-Term Use

Teva Pharmaceuticals presented new data from the Phase 3 SOLARIS trial for its long-acting injectable formulation TEV-'749, showing that over half of participants achieved stabilization and more than 20% met remission criteria after six months of treatment. The findings, which emphasize the efficacy and safety of TEV-'749 for schizophrenia, were shared at the Psych Congress from September 15-19, 2026. Teva is anticipating an FDA approval decision in Q4, reinforcing its commitment to innovation in neuroscience.